[go: up one dir, main page]

WO2006013736A1 - Levure mutante, procédé pour produire une levure riche en glutathion, culture de celle-ci, fraction de celle-ci, nourritures et boissons contenant extrait de levure et glutathion. - Google Patents

Levure mutante, procédé pour produire une levure riche en glutathion, culture de celle-ci, fraction de celle-ci, nourritures et boissons contenant extrait de levure et glutathion. Download PDF

Info

Publication number
WO2006013736A1
WO2006013736A1 PCT/JP2005/013471 JP2005013471W WO2006013736A1 WO 2006013736 A1 WO2006013736 A1 WO 2006013736A1 JP 2005013471 W JP2005013471 W JP 2005013471W WO 2006013736 A1 WO2006013736 A1 WO 2006013736A1
Authority
WO
WIPO (PCT)
Prior art keywords
yeast
dartathione
culture
yeast mutant
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2005/013471
Other languages
English (en)
Japanese (ja)
Inventor
Kazue Yamamoto
Kaori Yoshimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Breweries Ltd
Original Assignee
Asahi Breweries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2004226059A external-priority patent/JP4620405B2/ja
Priority claimed from JP2004226057A external-priority patent/JP4620404B2/ja
Application filed by Asahi Breweries Ltd filed Critical Asahi Breweries Ltd
Priority to KR1020077004875A priority Critical patent/KR101167345B1/ko
Priority to BRPI0513617-2A priority patent/BRPI0513617A/pt
Publication of WO2006013736A1 publication Critical patent/WO2006013736A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Definitions

  • Yeast mutant method for producing yeast having high glutathione content, culture thereof, fraction thereof, yeast extract and food and drink containing glutathione
  • the present invention relates to a yeast mutant of the genus Candida. More specifically, a mutant strain of Candidutilis that can contain a large amount of reduced or acidic salt type dartathione in the microbial cells, a culture obtained by culturing the mutant strain, a fraction, a yeast extract and the like are used. Related to food and drink. Background art
  • Glutathione is a tripeptide composed of three amino acids: glutamic acid, glycine, and cysteine. It is widely distributed in tissues such as the liver and muscles of yeast and animals, and is detoxified and reduced in acid in vivo. Involved in equilibrium action. Focusing on this physiological activity, daltathion has been widely used as a therapeutic agent for liver diseases such as a therapeutic agent for alcoholic fatty liver.
  • Conventionally known methods for producing yeast having a high content of dartathione include a method of adding an amino acid to a medium (Patent Document 1), a method of restricting zinc ions (Patent Document 2), and a culture temperature lower than usual. There is a method of culturing (Patent Document 3). In addition, there are ethionine 'sulfite resistant strains (Patent Document 4) and polyene antibiotic resistant strains (Patent Document 5) by mutagen treatment.
  • Patent Document 1 Japanese Patent Laid-Open No. 53-94089
  • Patent Document 2 JP-A-1 141591
  • Patent Document 3 JP-A-60-156379
  • Patent Document 4 Japanese Patent Laid-Open No. 59-151894
  • Patent Document 5 Japanese Patent Laid-Open No. 2003-284547
  • an object of the present invention is to provide a fermented mother that can retain a large amount of dartathione in a microbial cell and a dartathione-containing food or drink using the same yeast.
  • yeast mutants having cadmium resistance or macrolide antibiotic resistance are contained in a larger amount of cells than general wild yeast. It was found that dartathione can be contained, and the present invention has been completed.
  • the present invention is as follows.
  • a yeast mutant strain that has resistance to cadmium or macrolide antibiotics and can contain a high concentration of dartathione.
  • yeast mutant according to (1), wherein the yeast mutant having cadmium resistance is Candida utilis ABYC1560 (Accession No. FERM P-20094).
  • the yeast mutant having the resistance to macrolide antibiotics is Candida utilis.
  • the yeast mutant according to (1) which is ABYC1561 (Accession No. FERM P-20095).
  • the yeast mutant strain according to any one of (1) to (5) is aerobically cultured, and dartathione is accumulated at a high concentration in the yeast cell.
  • the yeast mutant according to any one of (1) to (5) is cultured under aerobic conditions. A fraction of the culture containing the resulting dartathione.
  • the novel yeast mutant strain of the present invention can contain daltathione at a high concentration in the microbial cells.
  • the novel yeast mutant strain of the present invention is aerobically cultured and cultivated in the yeast microbial cells. Dalthione can be accumulated at high concentrations.
  • the novel yeast mutant of the present invention can be cultured under aerobic conditions to obtain a culture or a fraction containing a high concentration of dartathione.
  • a novel yeast mutant strain of the present invention can be cultured under aerobic conditions to obtain a yeast extract containing daltathione at a high concentration.
  • a culture obtained by culturing the novel yeast mutant of the present invention under aerobic conditions, a fraction of the culture containing dartathione, or the culture or fraction obtained by heat treatment It can be set as a dartathione containing food / beverage product by containing.
  • the novel yeast mutant of the present invention is a yeast mutant having cadmium resistance or macrolide antibiotic resistance and capable of containing dartathione at a high concentration.
  • the cadmium-resistant yeast mutant of the present invention is obtained by selecting Candida utilis 15-10 or the like as a parent strain and selecting a mutant strain having enhanced heavy metal resistance than the parent strain by mutation treatment. It is done.
  • mutagenesis is performed using mutagens such as ultraviolet rays, ionizing radiation, nitrous acid, nitrosoguanidine, and ethenyl methanesulfonate (hereinafter abbreviated as "EMS").
  • mutagens such as ultraviolet rays, ionizing radiation, nitrous acid, nitrosoguanidine, and ethenyl methanesulfonate (hereinafter abbreviated as "EMS").
  • EMS ethenyl methanesulfonate
  • the amount of dartathione contained in the cells of the selected mutant strain is measured, a mutant strain having an increased amount of dartathione is further selected, and a mutant strain that can contain daltathione at a high concentration is searched.
  • a heavy metal used at this time cadmium, mercury, or the like is used.
  • a novel mutant, Candidutilis ABYC1560 was obtained.
  • the mutant Candida utilis ABYC1560 of the present invention contains 0.
  • dartathione in the present invention means the total amount of dartathione of reduced type and acid type dartathione.
  • the general bacteriological properties of the novel mutant Candida utilis ABYC1560 strain of the present invention are exactly the same as the general bacteriological properties of Candida utilis except for cadmium resistance.
  • the novel mutant Candida utilis ABYC1560 strain of the present invention is designated as “Accession number FERM”.
  • the yeast mutant of the present invention may be any one as long as it has resistance to macrolide antibiotics and can contain a large amount of oxidized and reduced darthathione in the microbial cells.
  • Candida utilis ABYC 1561 obtained by mutation treatment using Candida utilis ABYC1560 as a parent strain can be mentioned.
  • the macrolide antibiotic is an antibiotic having macrocyclic ratatones, and examples of the macrolide antibiotic of the present invention include rapamycin, reinamycin, and lankacidin C.
  • yeast mutant strain having resistance to the macrolide antibiotic of the present invention specifically, mutagen such as ultraviolet ray, ionizing radiation, nitrous acid, nitrosoguanidine, EMS, etc. is used.
  • a strain that has grown on an agar medium containing an antibiotic is selected.
  • the amount of dartathione contained in the cells of the selected mutant strain is measured, a mutant strain with an enhanced amount of dartathione is further selected, and a mutant strain that can contain daltathione at a high concentration is searched.
  • a novel mutant Candida utilis ABYC1561 was obtained.
  • Mutant Candida utilis ABY having resistance to macrolide constituents of the present invention C1561 accumulates 0.5 wt% or more of dartathione per dry weight in the microbial cells.
  • dartathione in the present invention means the total amount of dartathione of reduced type and acid type dartathione.
  • novel mutant Candida utilis ABYC1561 strain of the present invention are exactly the same as the general bacteriological properties of Candida utilis except for resistance to macrolide antibiotics. It is.
  • the novel mutant Candida utilis ABYC1561 strain of the present invention is designated as ⁇ Accession No.
  • the present invention further provides a method for producing yeast having a high content of dartathione, wherein the mutant strain is aerobically cultured.
  • the present invention further provides a method for producing a yeast having a high content of dartathione, wherein the yeast mutant strain is aerobically cultured.
  • the cadmium-resistant mutant strain or macrolide antibiotic-resistant mutant strain obtained by the above-described method may be aerobically cultured in a medium containing a carbon source, a nitrogen source, an inorganic salt, and the like. .
  • the medium composition of these strains is one or more selected from the group consisting of glucose, sucrose, acetic acid, ethanol, molasses, and sulfite pulp waste liquor, which are used as a carbon source for the cultivation of ordinary microorganisms.
  • nitrogen source inorganic salts such as urea, ammonia, ammonium sulfate, ammonium chloride or ammonium phosphate, and corn staple (CSL), casein, yeast extract or One or more selected from the group consisting of nitrogen-containing organic substances such as peptone are used.
  • phosphoric acid component, potassium component, magnesium component may be added to the medium, such as normal calcium phosphate, phosphate, potassium chloride, potassium hydroxide, magnesium sulfate, magnesium hydrochloride, etc.
  • Industrial raw material of inorganic salts such as zinc, copper, manganese, and iron ions may be used.
  • vitamins and nucleic acid-related substances may be added.
  • the culture format may be any of batch culture, fed-batch culture or continuous culture, but industrially fed-batch culture or continuous culture is employed.
  • the culture temperature may be in accordance with general yeast culture conditions. For example, 20 to 40 ° C, preferably 25 to 35 ° C is preferable.
  • the pH is 3.5 to 8.0, particularly 4.0 to 6.0.
  • a fraction containing glutathione may be obtained from the strength of the culture that can produce a culture containing a high concentration of dalutathione in yeast.
  • any method can be used as long as it is usually performed! Can be mentioned.
  • by loading the obtained extract on a carrier it can be concentrated to a fraction containing daltathione at a high concentration.
  • a yeast extract may be prepared from the culture cultured by the above method.
  • any method may be used as long as it is a conventional method, but an autolysis method, an enzymatic decomposition method, an alkali extraction method, or the like is industrially employed.
  • dry yeast cells may be prepared from the culture cultured by the above method!
  • any method may be used as long as it is a conventional method, but industrially, freeze drying method, spray drying method, drum drying method, etc. Is adopted.
  • the present invention relates to a culture obtained by culturing the yeast mutant under aerobic conditions, and a food or drink containing a fraction of the culture containing glutathione.
  • These foods and drinks may be any foods and drinks to which dry yeast or yeast extract can be added.
  • a culture obtained by culturing the yeast mutant strain under aerobic conditions, or a fraction of the culture containing daltathione. May be added.
  • the cell weight was measured from the weight after the culture solution was washed twice with a centrifuge and then dried at 105 ° C for 5 hours.
  • Total dartathio combined with reduced and oxidized dartathione Quantification was measured according to the method of Titze et al. (“Analytical Biochemistry”, Vol. 27, page 502, 1969).
  • the total amount of dartathione (% / ⁇ ) in the dry cells was calculated by dividing the total amount of dartathione obtained by the dry cell weight, and was used as a percentage.
  • Candidutilis was cultured until the logarithmic growth phase in a test tube containing YPD medium (glucose 2%, polypeptone 2%, yeastex 1%). Thereafter, the cells were collected and subjected to mutation treatment using EMS according to a conventional method. Mutation treatment was performed under conditions that resulted in a death rate of approximately 70%.
  • the 15-10 strain subjected to the mutation treatment as described above was inoculated into YP D medium containing 0.2 mg / ml of cadmium and statically cultured at 30 ° C for 48 hours. As a result, 200 cadmium-resistant mutant strains were isolated. With respect to these cadmium-resistant mutant strains, the total amount of dartathione was measured by the above-mentioned method, and ABYC1560 strain (accession number FERM P-20094) in which the amount of dartathione in the cells was increased was obtained.
  • P-20094 and its parent strain 15-10 were precultured in YPD medium for 18 hours, then inoculated into YPD medium, and main culture was performed at 30 ° C for 18 hours.
  • the cultured cells were collected by centrifugation, washed twice with water, boiled in a boiling water bath for 5 minutes, extracted from the cells, and the total amount of dartathione was measured according to the method described above.
  • the total amount of dartathione in dry cells is 0.52 wt% in the parent strain (15-10), whereas the cadmium resistant strain (ABYC1560 strain (accession number FE RM
  • Candidutilis was cultured until the logarithmic growth phase in a test tube containing YPD medium (glucose 2%, polypeptone 2%, yeastex 1%). The cells were collected and subjected to mutation treatment using EMS according to a conventional method. Mutation treatment was performed under the condition that the death rate was about 70%.
  • the ABYC1560 strain which was mutated as described above, contained 1 ⁇ g / ml rapamycin.
  • the inoculated YPD agar medium was incubated at 30 ° C for 48 hours. As a result, 745 rapamycin resistant mutants were isolated. With respect to these resistant strains, the total amount of dalutathione was measured by the method described above, and ABYC1561 strain (Accession No. FERM P-20095) with an increased amount of intracellular dalutathione was obtained.
  • the ABYC 1561 strain that acquired rapamycin resistance and its parent strain ABYC 1560 strain were pre-cultured in YP D medium for 18 hours, then inoculated into YPD medium, and main culture was performed at 30 ° C for 18 hours.
  • the cultured cells were collected by centrifugation, washed twice with water, boiled in a boiling water bath for 5 minutes, extracted from the cells, and the total amount of dartathione was measured according to the method described above.
  • the total amount of dartathione in the dried cells is 1.00% in the parent strain (ABYC1560), while the rapamycin metabolite (ABYC1561 (accession number FERM
  • the present invention has industrial applicability in the following points.
  • the novel yeast mutant of the present invention can contain daltathione at a high concentration in the microbial cells, and the novel yeast mutant of the present invention is aerobically cultured in the yeast microbial cells. Dalthione can be accumulated at high concentrations.
  • the novel yeast mutant of the present invention can be cultured under aerobic conditions to obtain a culture or fraction containing a high concentration of dartathione.
  • a novel yeast mutant of the present invention can be cultured under aerobic conditions to obtain a yeast extract containing daltathione at a high concentration.
  • a culture obtained by culturing the novel yeast mutant of the present invention under aerobic conditions, a fraction of the culture containing dartathione, or the culture or fraction obtained by heat treatment It can be set as a dartathione containing food / beverage product by containing.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Il est prévu de fournir une levure capable de fixer un grand montant de glutathion dans ses cellules. Une levure mutante qui est tolérant au cadmium ou aux antibiotiques macrolides et pouvant contenir un grand montant de glutathion.
PCT/JP2005/013471 2004-08-02 2005-07-22 Levure mutante, procédé pour produire une levure riche en glutathion, culture de celle-ci, fraction de celle-ci, nourritures et boissons contenant extrait de levure et glutathion. Ceased WO2006013736A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020077004875A KR101167345B1 (ko) 2004-08-02 2005-07-22 효모 변이주, 글루타티온 고함유 효모의 제조방법, 그배양물, 그 분획물, 효모 엑기스 및 글루타티온 함유음식품
BRPI0513617-2A BRPI0513617A (pt) 2004-08-02 2005-07-22 grupo de levedura mutante, método para produção de levedura rica em glutationa, cultura e fração da mesma, extrato de levedura, células de levedura seca e alimento e bebida contendo glutationa

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004226059A JP4620405B2 (ja) 2004-08-02 2004-08-02 酵母変異株、グルタチオン高含有酵母の製造方法、その培養物、その分画物、酵母エキスおよびグルタチオン含有飲食品
JP2004226057A JP4620404B2 (ja) 2004-08-02 2004-08-02 酵母変異株、グルタチオン高含有酵母の製造方法、その培養物、その分画物、酵母エキスおよびグルタチオン含有飲食品
JP2004-226059 2004-08-02
JP2004-226057 2004-08-02

Publications (1)

Publication Number Publication Date
WO2006013736A1 true WO2006013736A1 (fr) 2006-02-09

Family

ID=35787027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/013471 Ceased WO2006013736A1 (fr) 2004-08-02 2005-07-22 Levure mutante, procédé pour produire une levure riche en glutathion, culture de celle-ci, fraction de celle-ci, nourritures et boissons contenant extrait de levure et glutathion.

Country Status (3)

Country Link
KR (1) KR101167345B1 (fr)
BR (1) BRPI0513617A (fr)
WO (1) WO2006013736A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010116833A1 (fr) 2009-04-08 2010-10-14 Ajinomoto Co., Inc. Nouvelle levure ayant une teneur accrue de composé soufré, procédé de criblage permettant de l'identifier et procédé de culture
EP2554656A4 (fr) * 2010-03-26 2014-03-26 Asahi Group Holdings Ltd Procédé de culture de levure
WO2014144210A3 (fr) * 2013-03-15 2014-12-04 Butamax Advanced Biofuels Llc Croissance compétitive et/ou avantage de production pour des microorganismes générant du butanol
JP2019119052A (ja) * 2017-12-28 2019-07-22 コニカミノルタ株式会社 吐出設定方法、データ処理装置及びインクジェット記録装置

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101316806B1 (ko) * 2011-08-02 2013-10-10 (주)이뮤노텍 글루타치온과 실리마린을 유효성분으로 함유하는 항산화 및 간보호용 조성물
KR101640846B1 (ko) 2015-12-30 2016-07-20 에이테크 주식회사 히트파이프를 이용한 주방용 가열기기

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59151894A (ja) * 1983-02-18 1984-08-30 Kohjin Co Ltd グルタチオン高含有酵母の製造法
JP2000279164A (ja) * 1999-03-31 2000-10-10 Kohjin Co Ltd 酵母の製造方法
JP2005073638A (ja) * 2003-09-02 2005-03-24 Ajinomoto Co Inc キャンディダ・ユティリスのグルタチオン合成酵素をコードする遺伝子

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59151894A (ja) * 1983-02-18 1984-08-30 Kohjin Co Ltd グルタチオン高含有酵母の製造法
JP2000279164A (ja) * 1999-03-31 2000-10-10 Kohjin Co Ltd 酵母の製造方法
JP2005073638A (ja) * 2003-09-02 2005-03-24 Ajinomoto Co Inc キャンディダ・ユティリスのグルタチオン合成酵素をコードする遺伝子

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MEHR R.K. AND WINGER D.R.: "Metal ion resistance in fungi: Molecular mechanisms and their regulated expression", J CELL BIOCHEM., vol. 45, no. 1, 1991, pages 30 - 40, XP002991096 *
MIYAKE T. ET AL: "Involvement of the VDE Homing Endonuclease and Rapamycin in Regulation of the Saccharomyces cerevisiae GSH11 Gene Encoding the High Affinity Glutathione Transporter", J BIOL. CHEM., vol. 278, no. 41, 10 October 2003 (2003-10-10), pages 39632 - 39636, XP002991094 *
PENNINCKX M.J.: "An overview on glutathione in Saccharomyces versus non-conventional yeasts", FEMS YEAST RES., vol. 2, no. 3, 2002, pages 295 - 305, XP002991095 *
VIDO K. ET AL: "A Proteome Analysis of the Cadmium Response in Saccharomyces cerevisiae", J BIOL CHEM, vol. 276, no. 11, 16 March 2001 (2001-03-16), pages 8469 - 8474, XP002991093 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010116833A1 (fr) 2009-04-08 2010-10-14 Ajinomoto Co., Inc. Nouvelle levure ayant une teneur accrue de composé soufré, procédé de criblage permettant de l'identifier et procédé de culture
EP2554656A4 (fr) * 2010-03-26 2014-03-26 Asahi Group Holdings Ltd Procédé de culture de levure
WO2014144210A3 (fr) * 2013-03-15 2014-12-04 Butamax Advanced Biofuels Llc Croissance compétitive et/ou avantage de production pour des microorganismes générant du butanol
US9771602B2 (en) 2013-03-15 2017-09-26 Butamax Advanced Biofuels Llc Competitive growth and/or production advantage for butanologen microorganism
JP2019119052A (ja) * 2017-12-28 2019-07-22 コニカミノルタ株式会社 吐出設定方法、データ処理装置及びインクジェット記録装置

Also Published As

Publication number Publication date
BRPI0513617A (pt) 2008-05-13
KR20070047811A (ko) 2007-05-07
KR101167345B1 (ko) 2012-07-19

Similar Documents

Publication Publication Date Title
US9084435B2 (en) Yeast mutant and yeast extract
JP5883780B2 (ja) 酵母の培養方法
JP5940780B2 (ja) 石川県の伝統発酵食品から分離した乳酸菌、その培養物及びその利用
JP5102076B2 (ja) サッカロマイセス・セレビシエ変異株、及び該変異株を用いたｒｎａ高含有酵母の製造方法。
WO2006013736A1 (fr) Levure mutante, procédé pour produire une levure riche en glutathion, culture de celle-ci, fraction de celle-ci, nourritures et boissons contenant extrait de levure et glutathion.
JP4620405B2 (ja) 酵母変異株、グルタチオン高含有酵母の製造方法、その培養物、その分画物、酵母エキスおよびグルタチオン含有飲食品
JP4620404B2 (ja) 酵母変異株、グルタチオン高含有酵母の製造方法、その培養物、その分画物、酵母エキスおよびグルタチオン含有飲食品
JP4434927B2 (ja) γ−アミノ酪酸含有食品の製造方法、及びγ−アミノ酪酸高生成能を有する酵母
KR102754662B1 (ko) 높은 트리펩타이드 생산능을 갖는 미생물 및 이의 용도
EP1018546B1 (fr) Micro-organismes produisant l'acide 5-aminolevulinique et procedes de production de cet acide a l'aide de ces micro-organismes
AU2014256403B2 (en) Yeast mutant and yeast extract
JP5667365B2 (ja) サッカロマイセス・セレビシエ変異株、及び該変異株を用いた含硫化合物高含有酵母の製造方法。
JP2008178314A (ja) 新規ウリカーゼの製造方法
WO2012067106A1 (fr) Procédé de fabrication d'un extrait de levure
KR102278292B1 (ko) 아세트알데하이드를 분해능 및 글루타치온 생성능을 가지는 적응진화된 효모및 이의 용도
JP6906348B2 (ja) 酵母の改良方法
US20120115191A1 (en) Production of fructo-oligosaccharide and derivatives by use of aspergillus spp

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200580022126.8

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1200700261

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1020077004875

Country of ref document: KR

122 Ep: pct application non-entry in european phase
ENP Entry into the national phase

Ref document number: PI0513617

Country of ref document: BR